Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2023-08-18 Major Shareholding Noti…
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements of a major shareholder (Song Kee Ryoung) in SCM Lifescience Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-08-18 Korean
[기재정정]증권신고서(지분증권) (2023.08)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment filed by SCM Life Science Co., Ltd. It explicitly states it is a 'Correction Report' (정정신고) to update information based on the 2023 semi-annual report. In the context of financial filings, a Securities Registration Statement is a regulatory document required for public offerings or capital changes. Since it does not fit into the specific categories like 10-K, IR, or others, and is a formal regulatory filing submitted to the financial authorities, it is classified as a Regulatory Filing (RNS).
2023-08-16 Korean
[기재정정]주요사항보고서(유무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from SCM Life Science Co., Ltd. regarding a correction (정정신고) to a previously filed capital increase (both paid-in and bonus issuance). It details specific changes to dates (신주배정기준일, 신주의 상장 예정일) and provides comprehensive terms for the capital increase. Since this is a formal regulatory filing detailing changes to capital structure and share issuance, it falls under the 'Share Issue/Capital Change' category.
2023-08-11 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for SCM Lifescience, covering the period from 2023.01.01 to 2023.06.30. It contains detailed company information, history, capital changes, and governance details, which are characteristic of an interim financial report. It is not an announcement of a report, but the report itself, containing substantive financial and operational data. H1 2023
2023-08-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Director's Dealing' or 'Insider Trading' report) where company executives disclose their personal transactions in the company's securities. It details the reporter (Jeon Myoung Shiin), their relationship to the company (Executive Director), and the specific changes in their share/securities holdings. This fits the definition of 'Director's Dealing' (DIRS).
2023-08-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Oh Hyoung-nam) of SCM Lifescience. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors/executives, which corresponds to the 'Director's Dealing' category.
2023-08-04 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.